US4629624A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inert matrix based on polycaprolactone for the oral administration of a drug, and method for the preparation of the galenic form comprising this matrix
Assignee: STYLED LABORATOIRE D'HYGIENE ET DE DIETETIQUE (LHD) - A FRENCH CORP SA
•
Filing: 1984-12-26
•
Granted: 1986-12-16
•
Expires: 2004-12-26
Abstract
Abstract The present invention relates to a new inert matrix having adjustable porosity and hardness. This matrix comprises polycaprolactone having an average molecular weight of between 2000 and 70,000, which is in the form of agglomerated grains having an average diameter of between 50 and 500 mu m and has a degree of crystallinity of at least 75%. The invention relates to the method for the preparation of a porous galenic form by means of the said matrix.
Inventors
- 👤 Herve Grouiller
- 👤 Fabien Christ
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 20:33
CPC Classifications
A; A61; A61K; A61K31/00; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
62 words
An inert polycaprolactone matrix for the oral administration of a drug, in which matrix, which has adjustable porosity and hardness, the polycaprolactone which it contains has a molecular weight of between about 2000 and 70,000, is in the form of agglomerated grains having an average diameter of between 50 and 500 μm and has a degree of crystallinity of at least 75%.
Claim 2
Dependent Claim
62 words
An inert polycaprolactone matrix for the oral administration of a drug, in which matrix, which has adjustable porosity and hardness, the polycaprolactone which it contains has a molecular weight of between about 2000 and 70,000, is in the form of agglomerated grains having an average diameter of between 50 and 500 μm and has a degree of crystallinity of at least 75%.
Claim 3
Dependent Claim
25 words
The matrix as claimed in claim 1, which has been subjected to compression under a pressure greater than or equal to 100 daN/cm 2 .
Claim 4
Dependent Claim
24 words
The matrix as claimed in claim 1, which has been subjected to compression under a pressure of between 200 and 2000 daN/cm 2 .
Claim 5
Dependent Claim
23 words
The matrix as claimed in claim 1, wherein the polycaprolactone which it contains has an average molecular weight of between 30,000 and 45,000.
Claim 6
Dependent Claim
31 words
The matrix as claimed in claim 1, wherein the average diameter of the pores made up of the interstices present between the polycaprolactone grains is between 0.002 μm and 100 μm.
Claim 7
Dependent Claim
20 words
The matrix as claimed in claim 1, wherein the polycaprolactone has a degree of crystallinity of between 80 and 95%.
Claim 8
Dependent Claim
34 words
The matrix as claimed in claim 1, which has been subjected to a heat treatment at a temperature of between 45° and 70° C. for a period less than or equal to 20 minutes.
Claim 9
Dependent Claim
36 words
The matrix as claimed in claim 1, which has been subjected to treatment with an ultra-high frequency field of about 1 MHz to about 25 GHz for a period less than or equal to 60 seconds.
Claim 10
Dependent Claim
22 words
The matrix as claimed in claim 8, wherein the treatment is carried out for a period of between 10 and 60 seconds.
Claim 11
Dependent Claim
68 words
A method for the preparation of a porous galenic form for oral administration by means of a polycaprolactone matrix as claimed in claim 1 which comprises: (a) granulating a mixture comprising the caprolactone having an average molecular weight of 2,000 to 70,000, the drug, a lubricant, and a flow promoter; and (b) subjecting the resulting mixture to compression under a pressure of 100 to 2000 daN/cm 2 .
Claim 12
Dependent Claim
35 words
The method as claimed in claim 10, wherein the proportion of drug in the mixture of stage (a) is less than or equal to 80% by weight relative to the weight of the said mixture.
Claim 13
Dependent Claim
32 words
The method as claimed in claim 10, wherein the proportion of lubricant in the mixture of stage (a) is between 0.1 and 2% by weight relative to the weight of said mixture.
Claim 14
Dependent Claim
33 words
The method as claimed in claim 10, wherein the proportion of flow promoter in the mixture of stage (a) is between 0.1 and 2% by weight relative to the weight of said mixture.
Claim 15
Dependent Claim
23 words
The method as claimed in claim 13, wherein the proportion of lubricant in the mixture of stage (a) is about 0.5% by weight.
Claim 16
Dependent Claim
31 words
The method as claimed in claim 13, wherein the proportion of flow promoter in the mixture of stage (a) is about 0.5% by weight relative to the weight of said mixture.
Claim 17
Dependent Claim
96 words
A method for the preparation of a porous galenic form for oral administration by means of a polycaprolactone matrix as claimed in claim 1 which comprises: (a) granulating a mixture comprising the polycaprolactone having an average molecular weight of 2,000 to 70,000, the drug, a lubricant, and a flow promoter; (b) subjecting the resulting mixture to compression under a pressure of 100 to 2000 daN/cm 2 ; and (c) subjecting the resulting tablets to a heat treatment at a temperature of between 45° and 70° C. for a period less than or equal to 20 minutes.
Claim 18
Dependent Claim
99 words
A method for the preparation of a porous galenic form for oral administration by means of a polycaprolactone matrix as claimed in claim 1 which comprises: (a) granulating a mixture comprising the polycaprolactone having an average molecular weight of 2,000 to 70,000, the drug, a lubricant, and a flow promoter; (b) subjecting the resulting mixture to compression under a pressure of 100 to 2000 daN/cm 2 ; and (c) subjecting the resulting tablets to treatment with an ultra-high frequency field of about 1 MHz to about 25 GHz for a period of less than or equal to 60 seconds.
Claim 19
Dependent Claim
26 words
The method according to claim 17, wherein the treatment with an ultra-high frequency field is carried out for a period of between 10 and 60 seconds.
References Cited (Backward Citations)
FR1490855A
Cited
US3773919A
Cited
US3929937A
Cited
FR2363251A1
Cited
FR2377431A1
Cited
US4264574A
Cited
US4148871A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-12-15 | 1990-06-16 | 1990-12-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-12-15 | 1994-06-16 | 1994-12-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-12-15 | 1998-06-16 | 1998-12-16 | $7700.00 | Window Closed / Lapsed |